Molecular Playground/IntegrinBeta1: Difference between revisions
No edit summary |
No edit summary |
||
Line 18: | Line 18: | ||
==Integrins and cancer== | ==Integrins and cancer== | ||
Integrins binding to the extracellular matrix provide cells the ability to migrate and remodel the surrounding microenvironment. Integrins are extremely important in cancer metastasis and the progression of solid tumors. Cells bind to extracellular matrix proteins, like<scene name='60/609772/Rgd_bound/2'> peptide RGD (black) on fibronectin</scene>, with integrins to stimulate survival, migration/invasion, and proliferation <ref>PMID:20029421</ref>. Though high expression of integrin beta 1 has been shown to drive primary tumor progression and metastasis, targeting integrins for cancer treatment has seen limited clinical efficacy <ref>PMID:22894137</ref>. These failures stem from differential integrin expression between cancer cells, but new technologies to screen cancer cell populations are being developed to affective therapies on a patient-specific level <ref> Barney LE, Dandley EC, Jansen LE, Reich NG, Mercurio AM, Peyton SR. “A Cell-ECM Screening Method to Predict Breast Cancer Metastasis”. (2014) In Review.</ref>. These technologies will likely allow for more selective treatment and better clinical efficacy for integrin inhibitors. [[Image:B1_tissue.png | | Integrins binding to the extracellular matrix provide cells the ability to migrate and remodel the surrounding microenvironment. Integrins are extremely important in cancer metastasis and the progression of solid tumors. Cells bind to extracellular matrix proteins, like<scene name='60/609772/Rgd_bound/2'> peptide RGD (black) on fibronectin</scene>, with integrins to stimulate survival, migration/invasion, and proliferation <ref>PMID:20029421</ref>. Though high expression of integrin beta 1 has been shown to drive primary tumor progression and metastasis, targeting integrins for cancer treatment has seen limited clinical efficacy <ref>PMID:22894137</ref>. These failures stem from differential integrin expression between cancer cells, but new technologies to screen cancer cell populations are being developed to affective therapies on a patient-specific level <ref> Barney LE, Dandley EC, Jansen LE, Reich NG, Mercurio AM, Peyton SR. “A Cell-ECM Screening Method to Predict Breast Cancer Metastasis”. (2014) In Review.</ref>. These technologies will likely allow for more selective treatment and better clinical efficacy for integrin inhibitors. | ||
[[Image:B1_tissue.png|315 px|thumb|Fig. 1: Beta1 integrin expression in a human breast tumor stained in the Peyton Lab. Beta1 integrin (red) and DAPI (nucleus, blue)]] | |||
==Studying Integrin Beta-1'' in vitro''== | ==Studying Integrin Beta-1'' in vitro''== |